

Subject Index

3D TOF MRA 121

A

abciximab (ReoPro®) 250
 abciximab in emergent stroke
 treatment trial (AbESTT) 250
 accuracy and clinical utility of CTA
 in acute stroke 79
 accurate 80
 ADC 151
 adjunctive therapy 250
 advantages and disadvantages
 of CTA 59
 AIF computation 178
 airway protection 214
 albumin 14
 alteplase (rt-PA) 247, 249
 altered level of consciousness 210
 angioplasty balloon catheters 246
 anisotropy refers 156
 anterior circulation thrombolysis 251
 aortic dissection 33
 apoptogenic triggers 4
 apoptosis 4
 – caspase-dependent 6
 – caspase-independent 6
 apparent diffusion coefficient
 (ADC) 141
 argatroban 250
 arterial enhancement 117
 arterial input function (AIF) 178
 arterial spin labeling (ASL) 175
 artifact
 – stair step 65
 – zipper 65
 – zipper effect 70
 ASPECTS 50
 ATLANTIS 225
 atrial fibrillation 68
 atrial myxoma 34
 australian streptokinase trial
 (ASK) 224

B

background – general principles
 of CTA 59
 bacterial endocarditis 34
 balloon-assisted thrombolysis 245
 basilar scrape 35
 benign oligemia 103
 blood–brain barrier disruption 117
 bolus chaser 66
 bolus tracking 67
 brain swelling 117
 breathing 214
 bridging Trial 253
 Brownian motion 139

C

cardiovascular management 214
 carotid bruits 31
 carotid plaque 81
 carotid T occlusion 252
 caspases 5
 CBF 205
 CE MRA
 – time-resolved 126
 central volume principle 92
 cerebral blood flow (CBF) 88, 92, 203
 cerebral blood flow (rCBF) 200
 cerebral blood volume (CBV) 88, 92,
 203
 cerebral venous sinus thrombosis
 (CVT) 165
 characteristics of the initial
 symptoms 209
 chemical thrombolysis 243
 chlamydia 31
 cholesterol emboli 33
 cine CTA fluoroscopy 83
 circle of Willis 121
 clinical outcome 159
 clinical trials 223

coagulation cascade 221
 cocaine 30
 combined intravenous
 and intra-arterial thrombo-
 lysis 253
 concentric retriever 247
 cone beam effect 64
 contrast considerations 65
 contrast timing strategies 66
 contrast-enhanced MRA
 (CE MRA) 121, 126
 contrast-induced nephropathy
 (CIN) 62
 core 28, 264
 – ischemic 182
 cryptogenic stroke 27
 CT angiography (CTA) 205
 CT dose index (CTDI) 63
 CT early ischemic changes: detection
 and prognostic value 48
 CT technique 42
 CTA 80
 CTA protocol for acute stroke 64, 77
 CTA scanning technique:
 pearls and pitfalls 61
 CTP (CT perfusion) 205
 CTP post-processing 94
 curved reformat 73
 cystic cavitation 119
 cytotoxic edema 144

D

deconvolution techniques 93
 dehydration 214
 depolarization
 – anoxic 7
 – peri-infarct 7
 desmoteplase 193, 223, 225, 250
 – DIAS trial 12
 desmoteplase in acute ischemic stroke
 trial (DIAS) 57, 193

diabetes mellitus 30
 DIAS 193, 225, 263
 diethyleneamine pentaacetate (DTPA) 199
 diffusion constant 141
 diffusion tensor imaging (DTI) 142, 155
 dissection 82, 121
 dolichoectasia 32
 dose-length product (DLP) 63
 drug delivery 16
 drug overdose 210
 dynamic susceptibility contrast (DSC) imaging 174

E

early CT findings in hyperacute stroke 48
 ECASS 224
 echo planar imaging (EPI) 174
 EKOS MicroLys US infusion catheter 247
 emergency management of stroke (EMS) 253
 encephalopathy 210
 endocarditis
 – Libman–sacks 34
 – marantic 34
 endovascular photoacoustic recanalization (EPAR) 247
 EPI gradient-echo 174
 EPI spin-echo 174
 eptifibatid (Integrilin®) 250
 ethylcysteine dimer (ECD) 199
 exact time of onset 210

F

[F-18]-fluorodeoxyglucose (FDG) 202
 false-negative DWI images 148
 false-positive DWI images 149
 febrile illness 30
 fibrinoid necrosis 37
 fibroelastoma 35
 fibromuscular
 – dysplasia 33
 – dysplasia (FMD) 133
 fick principle 93
 fixed delay 67
 free radicals
 – oxygen free radicals 3

G

gadolinium-based contrast agent 174
 general considerations 64
 glutamate
 – ionotropic receptor 3
 glutamate receptor
 – AMPA-receptor 3
 – ionotropic receptor 3
 – NMDA receptor 3
 grading systems 255
 gray matter enhancement 118
 GRE T2* sequence 120
 guide catheter 243
 guidelines
 – for large strokes 226
 – for time of stroke onset greater than 3 h 226
 gyriform T1 high signal 119

H

hairline residual lumen 80
 hematoma 35
 hemorrhage 264
 hemorrhagic
 – conversion 35
 – transformation (HT) 119, 152, 190
 heparin 250
 herniation syndrome 36
 hexamethylpropyleneamine oxime (HMPAO) 199
 Hollenhorst plaques 32
 hyperacute 41
 hyperglycemia 214
 hyperlipidemia 30
 hypertension 30
 – induced 15
 hypo-osmolarity 214
 hypodensity 264
 hypoglycemia 210, 214
 hypothermia 14

I

i.a. thrombolysis (IAT) 238
 IAT in acute stroke 238
 image review 70
 implications for acute stroke triage 51
 infarct core 101
 inflammation 6
 interventional management of stroke (IMS) study 253

intra-arterial (i.a.) thrombolysis 57
 intracranial pressure (ICP) 214
 intraluminal thrombus 115
 iodixanol 65
 ischemic 3
 – core 182
 – edema 36
 – ienumbra 101, 182
 – pre-conditioning 13
 iso-osmolar agent 65

L

large vessel occlusion 264
 lepirudin 250
 lipohyalinosis 37

M

magnesium 14
 magnetic resonance spectroscopy (MRS) 199
 magnetic susceptibility 174
 marantic endocarditis 34
 Marfan's syndrome 33
 mass effect 118
 matrix 8
 mature thrombus 222
 maximum intensity projection 71
 mean transit time (MTT) 88, 92, 178, 203
 mechanical embolus removal in cerebral ischemia (MERCi) 247
 mechanical thrombolysis 244
 medical evaluation 215
 meningeal enhancement 117
 MERCI 247
 metalloproteinases 8
 microcatheter 243
 microwire 243
 microwire mechanical manipulation 243
 migrainous accompaniment 210
 mild induced hypertension 242
 mimics of stroke 210
 moya moya 39, 132
 MR fogging 117
 MR spectroscopy (MRS) 200, 205
 multi-slice protocols 63
 multicenter acute stroke trial
 – europe (MAST-E) 224
 – italy (MAST-I) 224
 multiplanar volume reformat 72

N

NCCT pitfalls 54
 neurologic assessment 215
 neuron
 – selective neuronal death 8
 neuroprotective trials 10
 neurotoxicity of t-PA 226
 neurovascular unit 8
 NINDS rt-PA stroke study 224
 nondeconvolution techniques 93
 nuclear magnetic resonance (NMR) 205

O

occluded internal carotid artery 81
 optimal image review 46, 79
 oxygen
 – free radicals 3
 – hyperbaric oxygen therapy 15
 – normobaric oxygen therapy 16

P

parenchymal
 – enhancement 118
 – hypodensity 45
 PC MRA 124, 125
 penetrator vessel 37
 penumbra 28, 101, 264
 – ischemic 182
 perfusion 173
 – abnormality 264
 – weighted magnetic resonance imaging (PWI) 173
 PET 200, 202
 phase IV studies 225
 phase-contrast MRA (PC MRA) 124, 125
 physical basis of imaging findings 45
 pitch 61
 pitfalls
 – NCCT 54
 plasmin
 – inhibitor 222
 plasminogen
 – activators (PA) 222
 positron emission tomography (PET) 199
 post-carotid endarterectomy hyperperfusion 201

post-processing: image reconstruction 70
 posterior
 – circulation thrombolysis 252
 – reversible encephalopathy syndrome (PRES) 161
 potential
 – advantages 59
 – disadvantages 59
 predicting tissue viability 182
 primary granulomatous angiitis 39
 PROACT I trial 251
 PROACT II trial 252
 prognostic/clinical significance 49
 prosthetic valve 34
 protocols for intra-arterial thrombolytics 256
 prourokinase (pro-UK) 249
 pseudo-aneurysm 33
 pseudonormalize 145

Q

quantum mottle 64

R

radiation dose considerations 63
 reading CT scans 52
 recanalization 81
 recombinant tissue plasminogen activator (rt-PA) 57
 recommendations for use of t-PA 226
 regional cerebral blood flow (rCBF) 178
 regional cerebral blood volume (rCBV) 178
 relevant past medical history 210
 residue function 93
 reteplase 249
 reversibility of DWI stroke lesions 150
 rheolytic thrombectomy device 247
 role of CTA in acute stroke 79

S

seizure 210
 self-diffusion 139
 shaded surface display 73
 single photon emission computed tomography (SPECT) 199
 single-shot echo planar (EPI) 141
 single-slice protocols 63

slow stroke 32
 snare 245
 specific uptake value (SUV) 203
 SPECT 199, 200
 spreading depression, cortical 7
 streptokinase (SK) 222, 249
 stroke mimics 159
 subclavian steal syndrome 32
 systemic lupus erythematosus 39

T

T2 lesion volume 151
 T2 shine through 144
 Takayasu's arteritis 39
 tandem lesions 81
 technetium-99m 199
 temporal arteritis 39
 tenecteplase 249
 test bolus 67
 thiamine deficiency 210
 thrombolysis 189, 201, 222
 thrombolysis or fibrinolysis 221
 thrombosis 221
 thrombus 80
 time course 146
 – of diffusion lesion 145
 time of symptom onset 209
 time to peak (TTP) 180
 time-of-flight (TOF) 121
 time-resolved CE MRA 126
 tissue plasminogen activator (t-PA) 222
 tobacco abuse 30
 Todd's paralysis 242
 trans-esophageal echocardiography (TEE) 83
 transcortical aphasia 36
 transformation 190
 – hemorrhagic 190
 transient
 – global amnesia 160
 – ischemic attack 159
 – monocular blindness 31
 triage of the stroke patient 209
 TTP 189
 tumor 210

U

urokinase (UK) 222, 243, 247

V

vascular
– dissection 131
– obstruction 215
vasculitis 133
vasodilatation 35
vasogenic edema 117
– syndromes 161
venous occlusion 134
volume rendering 73

W

Wallerian degeneration 119, 158
white matter, ischemia 8
windmill artifact 62
window-width (W) and center-level (L)
CT review settings 46

X

Xe-133 199
Xe-CT 200
xenon CT perfusion (Xe-CT) 199

Z

zipper effect 65, 70